Stifel Nicolaus Begins Coverage on Contineum Therapeutics (NASDAQ:CTNM)

Equities researchers at Stifel Nicolaus started coverage on shares of Contineum Therapeutics (NASDAQ:CTNM) in a report released on Tuesday, Briefing.com reports. The brokerage set a “buy” rating and a $29.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 81.25% from the stock’s previous close.

Contineum Therapeutics Stock Performance

CTNM stock opened at $16.00 on Tuesday. Contineum Therapeutics has a 12 month low of $13.90 and a 12 month high of $16.05.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).